VRCA

Business Context and Reporting Period

Verrica Pharmaceuticals Inc. (VRCA) is a dermatology therapeutics company focused on developing and selling medications for skin diseases. The reporting period covers the fiscal year ended December 31, 2024. The Company's primary commercial product is YCANTH (VP-102), approved by the FDA in July 2023 for the treatment of molluscum contagiosum. The Company is also developing YCANTH for common warts and VP-315 for basal cell carcinoma (BCC).

Key Financial Metrics

Revenue Breakdown: Product revenue (net) was $6.6 million, and collaboration revenue was $1.0 million. Liquidity: The Company raised $39.6 million in net proceeds from an equity offering in November 2024.

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased by $2.4 million (48%) driven by expanded distribution of YCANTH, though partially offset by a $3.2 million increase in product returns reserves due to lower sell-through and expiration.
• Operating Expenses: Selling, general, and administrative (SG&A) expenses increased by $11.5 million to $58.8 million, primarily due to commercial ramp-up costs ($8.5 million) and severance costs ($1.8 million) from a restructuring that reduced the sales force by approximately 29%.
• R&D Expenses: Research and development expenses decreased by $8.5 million to $11.8 million, reflecting reduced pre-approval costs for YCANTH and lower clinical costs for VP-315.
• Interest Expense: Interest expense increased by $5.5 million to $9.4 million due to the OrbiMed Credit Agreement and the recognition of a $2.6 million change in fair value of a derivative liability.

Guidance, Outlook, Risks, and Contingencies

Going Concern: Management has concluded that substantial doubt exists regarding the Company's ability to continue as a going concern within one year of the report date. While cash resources are $46.3 million, the Company expects to incur significant losses and requires additional funding to meet obligations, including a $10.0 million liquidity covenant under its debt agreement.

Debt Covenants: The Company is obligated to begin monthly principal payments on its $50.0 million OrbiMed loan starting January 1, 2025, as revenue targets were not met. The debt agreement includes a financial covenant requiring a minimum liquidity of $10.0 million and no "going concern" qualification (waived for 2024 and Q1 2025).

Outlook:

• YCANTH (Common Warts): A global Phase 3 trial is anticipated to begin as early as mid-2025, with costs shared equally with partner Torii Pharmaceutical Co., Ltd.
• VP-315 (BCC): Phase 2 data showed a 97% calculated Objective Response Rate. An end-of-Phase 2 meeting with the FDA is expected in the first half of 2025.
• Competition: Ligand Pharmaceuticals received FDA approval for Zelsuvmi (berdazimer) for molluscum contagiosum in January 2024, creating direct competition.

Legal Proceedings: The Company is defending a putative class action lawsuit regarding alleged manufacturing deficiencies and a related stockholder derivative lawsuit. A settlement was reached with Dormer Laboratories for $0.8 million.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $46.3 million cash balance against the $50.0 million debt principal payments commencing January 2025 and ongoing operating burn rate.
• Debt Covenant Compliance: Monitor the Company's ability to maintain the $10.0 million liquidity covenant and secure waivers for "going concern" qualifications in future quarters to avoid default.
• Product Returns: Assess the impact of the $3.2 million increase in returns reserves on future revenue recognition and gross margins.
• Equity Dilution: Review the terms of the November 2024 offering, including the 47.8 million Series A and B warrants, and the potential dilution from future financing needs.
• Commercial Execution: Evaluate the effectiveness of the reduced sales force (from 80 to ~35 territories) in driving YCANTH sell-through against new competition (Zelsuvmi).